Aclaris Therapeutics, Inc.ACRSNASDAQ
Loading
SG&A Expenses Over TimeStable
Percentile Rank42
3Y CAGR-4.4%
5Y CAGR+1.4%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
-4.4%/yr
vs -24.1%/yr prior
5Y CAGR
+1.4%/yr
Recent deceleration
Acceleration
+19.7pp
Accelerating
Percentile
P42
Within normal range
vs 5Y Ago
1.1x
Modest growth
Streak
2 yr
Consecutive declineStable
PeriodValueYoY Change
TTM$21.97M-1.0%
2024$22.20M-28.6%
2023$31.10M+23.7%
2022$25.13M+6.4%
2021$23.62M+15.0%
2020$20.53M-26.2%
2019$27.83M-63.2%
2018$75.65M+128.5%
2017$33.11M+119.4%
2016$15.09M-